The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

Pharmacoepidemiology and Drug Safety

Volume 26, Issue 6
Commentary
Open Access

Advancing regulatory science, advancing regulatory practice

Xavier Kurz

Corresponding Author

E-mail address: xavier.kurz@ema.europa.eu

European Medicines Agency, Department Pharmacovigilance and Epidemiology, London, UK

Correspondence to: Dr X. Kurz, European Medicines Agency, Department Pharmacovigilance and Epidemiology, 30 Churchill Place, Canary Wharf, London E145EU, UK. Email:

xavier.kurz@ema.europa.eu

Search for more papers by this author
First published: 21 February 2017
https://doi.org/10.1002/pds.4181
Cited by: 1
First page image

Number of times cited according to CrossRef: 1

  • Andrea Farcaş, Andreea Măhălean, Noémi Beátrix Bulik, Daniel Leucuta and Cristina Mogoșan, New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014–2017, Expert Review of Clinical Pharmacology, 10.1080/17512433.2018.1526676, (1-7), (2018).
    Crossref